Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ROIV Roivant Sciences Ltd.

盘后交易 05-26 18:52:52 EDT

29.67

-0.29

-0.98%

盘后29.67

+0.000.00%

18:01 EDT

最高30.35	最低29.31	成交量729.42万
今开29.98	昨收29.96	日振幅3.47%
总市值212.31亿	流通市值138.54亿	总股本7.16亿
成交额2.16亿	换手率1.56%	流通股本4.67亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":29.665,"timestamp":1779825600000,"preClose":29.96,"halted":0,"volume":7294173,"hourTrading":{"tag":"盘后","latestPrice":29.665,"preClose":29.665,"latestTime":"18:01 EDT","volume":1119039,"amount":33196208.007075,"timestamp":1779832919754,"change":0,"changeRate":0,"amplitude":0.012978},"delay":0,"changeRate":-0.009846461949265745,"floatShares":467000000,"shares":715701137,"eps":-0.539999,"marketStatus":"盘后交易","change":-0.295,"latestTime":"05-26 18:52:52 EDT","open":29.98,"high":30.35,"low":29.31,"amount":216358986.343662,"amplitude":0.034713,"askPrice":30.67,"askSize":8,"bidPrice":29.3,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-0.539999,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779840000000},"marketStatusCode":4,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":29.96,"preHourTrading":{"tag":"盘前","latestPrice":29.96,"preClose":29.96,"latestTime":"09:27 EDT","volume":1122,"amount":33941.26296,"timestamp":1779802070015,"change":0,"changeRate":0,"amplitude":0.021696},"postHourTrading":{"tag":"盘后","latestPrice":29.665,"preClose":29.665,"latestTime":"18:01 EDT","volume":1119039,"amount":33196208.007075,"timestamp":1779832919754,"change":0,"changeRate":0,"amplitude":0.012978},"volumeRatio":0.703426,"impliedVol":0.3301,"impliedVolPercentile":0.3745},"requestUrl":"/m/hq/s/ROIV","defaultTab":"news","newsList":[{"id":"1150102941","title":"异动解读 | Roivant Sciences盘中大涨15.99%，财报及关节炎药物进展提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1150102941","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150102941?lang=zh_cn&edition=full","pubTime":"2026-05-21 01:05","pubTimestamp":1779296717,"startTime":"0","endTime":"0","summary":"生物制药公司Roivant Sciences Ltd.（ROIV）今日盘中股价大幅上涨15.99%，表现强劲。消息面上，公司公布了截至2026年3月31日的第四季度及全年财务业绩，并同步更新了业务进展。尽管第四季度营收低于市场预期，但公司披露的业务动态获得了市场的积极评价。其中，路透社的市场快讯特别指出，其关节炎药物初步显示出积极效果，这一进展是推动股价走高的关键因素。Roivant Sciences是一家通过构建技术平台来加速开发变革性药物的公司，此次财报与研发进展的披露，显著增强了投资者对其未来增长潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182026444","title":"异动解读｜Roivant Sciences盘中上涨11.1%，公布财年业绩及业务进展获市场积极反应","url":"https://stock-news.laohu8.com/highlight/detail?id=1182026444","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182026444?lang=zh_cn&edition=full","pubTime":"2026-05-20 21:40","pubTimestamp":1779284409,"startTime":"0","endTime":"0","summary":"5月20日，Roivant Sciences盘中上涨11.1%，报30.48美元/股，成交额3466.28万美元。消息面上，公司公布了截至3月31日的第四财季及全年财务业绩，并同步更新业务动态。尽管营收不及预期，但公司披露的业务进展获得市场积极反应，推动股价走强。Roivant Sciences是一家注册于百慕大的生物制药公司，通过构建技术平台和培养人才推出专注的生物制药及健康技术子公司，致力于更快开发变革性药物。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150457356","title":"异动解读｜Roivant Sciences盘前上涨8.12%，公布财年业绩及业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1150457356","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150457356?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:38","pubTimestamp":1779277123,"startTime":"0","endTime":"0","summary":"5月20日，Roivant Sciences盘前上涨8.12%，报30.43美元/股，成交额170.13万美元。消息面上，公司公布了截至3月31日的第四财季及全年财务业绩。数据显示，第四财季持续运营每股收益为0.28美元，营收252万美元低于市场预期的382万美元。尽管营收不及预期，但公司同步披露的业务动态更新获得市场积极反应，推动股价走强。Roivant Sciences是一家注册于百慕大的生物制药公司，通过构建技术平台和培养人才推出专注的生物制药及健康技术子公司，致力于更快开发变革性药物。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174214400","title":"异动解读 | 公布财报及业务进展，Roivant Sciences盘前大涨9.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174214400","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174214400?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:19","pubTimestamp":1779275955,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 今日盘前股价大幅上涨9.89%，市场反应积极。消息面上，公司公布了截至2026年3月31日的第四季度及整个财年的财务业绩，并提供了最新的业务动态更新。这份财报和业务进展的披露，是推动股价在盘前交易时段走强的主要原因。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177836782","title":"Roivant公布2026财年第四季度及全年业绩，并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1177836782","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177836782?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:01","pubTimestamp":1779274892,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. 已公布其截至2026年3月31日的第四季度及整个财年的财务业绩，同时提供了公司最新的业务动态更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131297163","title":"财报前瞻｜Roivant Sciences Ltd.本季度营收预计大幅下滑，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1131297163","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131297163?lang=zh_cn&edition=full","pubTime":"2026-05-14 00:02","pubTimestamp":1778688156,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.将在2026年05月20日美股盘前发布最新季度财报，市场普遍关注营收与亏损趋势及管线推进节奏。公司上季度披露的主营收入构成中，“产品”收入为2,093.60万美元，“许可、里程碑和其他”收入为385.10万美元。公司目前主营业务亮点在于“产品”带来的持续性收入，收入体量显著高于许可类收入。“产品”收入是目前公司最具可持续性的来源，上季度达2,093.60万美元，占收入的84.46%，显示商业收入已成为常态化支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Roivant Sciences Ltd.本季度营收预计大幅下滑，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178419514","title":"Roivant Sciences Ltd. 将于2026年5月20日公布2026财年第四季度及全年业绩并提供业务更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1178419514","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178419514?lang=zh_cn&edition=full","pubTime":"2026-05-12 04:06","pubTimestamp":1778530011,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. 宣布，公司计划于2026年5月20日（星期三）发布截至2026年3月31日的第四季度及整个2026财年的财务业绩报告。届时，管理层还将提供最新的业务进展与战略更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121877200","title":"Roivant Sciences Ltd：牛皮癣3期顶线数据与干燥综合征3期研究启动预计于2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1121877200","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121877200?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:03","pubTimestamp":1775120599,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.近日披露了其研发管线的重要进展时间表。根据公司规划，针对牛皮癣（Niu）适应症的3期临床试验顶线数据，以及针对干燥综合征（Cs）适应症的3期研究启动，均预计在2026年下半年的日历年内完成。\n这一系列关键节点的设定，标志着公司在自身免疫性疾病领域的研发进入了加速阶段。两项研究的推进，将为Roivant Sciences Ltd.的核心产品线带来重要的临床验证，并可能为未来的商业化奠定基础。市场投资者正密切关注这些里程碑事件，它们对公司估值和长期发展前景具有潜在的重大影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136481161","title":"Roivant拓展Brepocitinib研发计划：启动LPP新2B/3期试验并公布Batoclimax治疗TED的3期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1136481161","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136481161?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:00","pubTimestamp":1775120417,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 宣布扩大其候选药物Brepocitinib的研发计划，将针对扁平苔藓样糠疹（LPP）开展一项新的2B/3期临床试验。同时，公司还公布了另一款药物Batoclimab用于治疗甲状腺眼病（TED）的3期研究结果。\n此次战略扩展彰显了Roivant致力于推进其创新疗法管线，以解决未满足的医疗需求。新启动的LPP试验旨在评估Brepocitinib对这一罕见炎症性瘢痕性脱发疾病的疗效与安全性。而Batoclimab在TED领域的积极3期数据，则为该药物的潜在应用提供了重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145816069","title":"《新英格兰医学杂志》发布Brepocitinib治疗皮肌炎的三期VALOR试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1145816069","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145816069?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:01","pubTimestamp":1774724471,"startTime":"0","endTime":"0","summary":"《新英格兰医学杂志》近日刊发了Brepocitinib在治疗皮肌炎方面的三期VALOR临床试验的积极数据。该研究结果展现了该药物在应对这一自身免疫性疾病方面的显著潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616076553","title":"莫德纳解决LNP专利纠纷 将支付22.5亿美元和解金","url":"https://stock-news.laohu8.com/highlight/detail?id=2616076553","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616076553?lang=zh_cn&edition=full","pubTime":"2026-03-04 21:35","pubTimestamp":1772631300,"startTime":"0","endTime":"0","summary":"莫德纳（Moderna，MRNA）同意向Roivant Sciences（ROIV）支付高达22.5亿美元，以解决与其COVID-19疫苗相关的脂质纳米颗粒知识产权索赔，从而避免了原定于下周进行的陪审团审判。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8a24082c651a012a7802d63b3e7455d1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-04/doc-inhpvtwp3803059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4007","SINA","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115450583","title":"Roivant Sciences董事会批准10亿美元股票回购计划，包含2025年6月授权的5亿美元额度","url":"https://stock-news.laohu8.com/highlight/detail?id=1115450583","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115450583?lang=zh_cn&edition=full","pubTime":"2026-03-04 05:17","pubTimestamp":1772572633,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 宣布，其董事会已正式批准一项总额高达10亿美元的股票回购计划。值得注意的是，此项授权中包含了该公司在2025年6月已批准的5亿美元回购额度。\n这一大规模的回购举措彰显了管理层对公司未来前景的坚定信心，并反映了其致力于通过资本回报为股东创造价值的承诺。通过回购并注销股票，公司有望提升每股收益，从而优化股东权益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ABUS","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121677386","title":"Roivant Sciences旗下Arbutus正评估于2026年第三季度向股东返还资本","url":"https://stock-news.laohu8.com/highlight/detail?id=1121677386","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121677386?lang=zh_cn&edition=full","pubTime":"2026-03-04 05:17","pubTimestamp":1772572631,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 旗下的生物制药公司 Arbutus Biopharma Corporation (ABUS) 目前正在积极评估一项资本返还计划。该计划旨在于2026日历年第三季度向公司股东返还资本。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139","ABUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175985973","title":"Priovant宣布FDA受理并授予Brepocitinib治疗皮肌炎新药申请优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1175985973","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175985973?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:00","pubTimestamp":1772539222,"startTime":"0","endTime":"0","summary":"生物制药公司Priovant今日宣布，美国食品药品监督管理局（FDA）已正式受理其口服TYK2/JAK1抑制剂Brepocitinib用于治疗成人皮肌炎的新药申请（NDA），并授予该申请优先审评资格。\n此次优先审评标志着Brepocitinib在针对这一罕见、衰弱性自身免疫性疾病的研发进程中迈出了关键一步。若获批，该药物有望为皮肌炎患者提供一种新的重要治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176652125","title":"异动解读 | 旗下药物二期研究显示积极成果，Roivant Sciences盘中大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176652125","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176652125?lang=zh_cn&edition=full","pubTime":"2026-02-10 04:09","pubTimestamp":1770667748,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  今日盘中股价大幅上涨5.02%，引起了市场的关注。消息面上，公司旗下Priovant Therapeutics公司宣布，其试验药物brepocitinib在针对皮肤结节病的二期研究中显示出积极成果。研究数据显示，在较高剂量下，患者的皮肤活动性得到显著改善。此外，公司另一家子公司Pulmovant也已完成针对肺动脉高压的实验性药物mosliciguat的二期试验患者招募工作。Priovant表示，计划在与美国食品药品监督管理局协商后，于2026年启动brepocitinib的第三阶段试验。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108390468","title":"异动解读 | 候选药物二期数据积极叠加财报亮眼，Roivant Sciences盘中大涨19.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108390468","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108390468?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:58","pubTimestamp":1770389893,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  今日盘中大涨19.68%，引起了市场的广泛关注。消息面上，公司公布了其候选药物Brepocitinib在治疗皮肤结节病的二期临床试验中取得突破性进展，达到主要疗效终点，患者皮肤病变严重程度获得显著改善。临床数据显示，Brepocitinib作为口服TYK2/JAK1抑制剂，在12周治疗期内表现出优越的安全性与耐受性。财务方面，本季度研发支出集中投向核心管线推进，其中Brepocitinib项目获得重点资源倾斜。这些积极进展共同提振了市场信心，推动了股价的显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133289755","title":"Roivant股价盘前飙升15.8%，实验性药物对罕见皮肤病显效及三季度业绩提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1133289755","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133289755?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:59","pubTimestamp":1770382753,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 股价在盘前交易时段大幅跃升15.8%，此番强劲表现主要受到两大利好因素驱动：其一，公司旗下实验性药物在针对一种罕见皮肤病的临床试验中展现出积极疗效；其二，公司最新公布的第三季度财务业绩超出市场预期。这两项进展共同点燃了投资者的热情，推动股价显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185422472","title":"异动解读 | 候选药物二期数据积极叠加财报亮眼，Roivant Sciences盘前大涨9.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1185422472","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185422472?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:09","pubTimestamp":1770379795,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  今日盘前股价大涨9.93%，引起了市场的广泛关注。消息面上，公司公布了其候选药物Brepocitinib在治疗皮肤结节病的二期临床试验中取得突破性进展，达到主要疗效终点，患者皮肤病变严重程度获得显著改善。临床数据显示，Brepocitinib作为口服TYK2/JAK1抑制剂，在12周治疗期内表现出优越的安全性与耐受性。财务方面，本季度研发支出集中投向核心管线推进，其中Brepocitinib项目获得重点资源倾斜。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148492221","title":"Roivant公布Brepocitinib治疗皮肤结节病的二期积极数据 同步披露2025财年第三季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1148492221","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148492221?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:07","pubTimestamp":1770379626,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  近日宣布其候选药物Brepocitinib在皮肤结节病治疗领域的二期临床试验取得突破性进展。该研究达到主要疗效终点，患者皮肤病变严重程度获得显著改善。与此同时，公司公布了截至2025年12月31日的第三季度财务报告，研发投入与营收增长呈现良性互动态势。临床数据显示，Brepocitinib作为口服TYK2/JAK1抑制剂，在12周治疗期内表现出优越的安全性与耐受性特征。财务方面，本季度研发支出集中投向核心管线推进，其中Brepocitinib项目获得重点资源倾斜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183978683","title":"Priovant计划与FDA沟通后推进关键项目，三期临床试验拟于2026年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1183978683","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183978683?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:05","pubTimestamp":1770379512,"startTime":"0","endTime":"0","summary":"生物制药公司Priovant近日宣布，在与美国食品药品监督管理局（FDA）进行深入交流后，公司计划将其核心项目Cs推进至关键阶段。根据最新规划，该项目预计将于2026年正式启动三期临床试验。这一进展标志着该疗法向商业化应用迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":0.0229},{"period":"1month","weight":0.0278},{"period":"3month","weight":0.1035},{"period":"6month","weight":0.4817},{"period":"1year","weight":1.7386},{"period":"ytd","weight":0.3806}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Roivant Sciences Ltd.于2020年7月6日在百慕大注册成立。该公司是一家生物制药公司，旨在加速药物的开发和商业化。公司的研发管线包括brepocitinib（一种JAK1和TYK2小分子抑制剂，正在接受FDA审查用于治疗皮肌炎，并处于治疗非感染性葡萄膜炎、皮肤结节病和 lichen planopilaris的后期开发阶段）、IMVT-1402（一种针对FcRn的全人源单克隆抗体，正在开发用于治疗IgG介导的自身免疫适应症）以及mosliciguat（一种吸入式sGC激活剂，正在开发用于治疗间质性肺病相关的肺动脉高压）。公司通过创建灵活的子公司来推进其研发管线，以开发和商业化其药物和技术。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.087601},{"month":4,"riseRate":0.833333,"avgChangeRate":0.021573},{"month":5,"riseRate":0.5,"avgChangeRate":0.035293},{"month":6,"riseRate":0.8,"avgChangeRate":0.015077},{"month":7,"riseRate":0.8,"avgChangeRate":0.040575},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}